Our data thus far demonstrate that USP22 protects EZH2, a known negative regulator of MHC-I expression (8), from ubiquitination-mediated proteasomal degradation, suggesting that USP22 promotes tumor evasion of CD8+ T cell antitumor immunity through potentiating EZH2-mediated MHC-I downregulation. Here, CD8A is linked to neoplasm.